Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Intra-Cellular Therapies $14.6 billion acquisition by Johnson & Johnson
We are advising Intra-Cellular Therapies on the transaction
Royalty Pharma $1.1 billion acquisition of its external manager and $3 billion share repurchase
We are advising Royalty Pharma on the transaction
BrainAurora Medical Technology HK$583 million IPO
We advised BrainAurora on its IPO and HKEX listing
Teoxane proposal to acquire Revance Therapeutics
We are advising Teoxane on the proposed acquisition
Olema Pharmaceuticals $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Precigen $79 million preferred stock and warrants offering
We advised Precigen on the private placement
Personalis $50 million at-the-market offering
The shares are listed on the Nasdaq Global Market
FTC clearance of Novo Nordisk acquisition of certain Catalent sites
We secured regulatory approval following a lengthy review
Revolution Medicines $750 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market